Close

Jefferies Maintains Buy Following an Analysis on Integra LifeSciences (IART) TEI Acquisition

June 29, 2015 8:35 AM EDT
Get Alerts IART Hot Sheet
Price: $34.67 -0.46%

Rating Summary:
    10 Buy, 13 Hold, 3 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 13 | Down: 10 | New: 11
Join SI Premium – FREE

Jefferies maintains a Buy rating and $67.00 price target on Integra LifeSciences (NASDAQ: IART) following a preliminary analysis of IART's TEI acquisition. Integra projects TEI revenues to grow high-single digits. The deal is expected to close in 3Q.

Analyst Raj Denhoy commented, "Our preliminary analysis of Integra's acquisition of TEI points to a good deal for the company. TEI adds to Integra's regenerative product portfolio and adds to the sales & marketing infrastructure in wound care ahead of the upcoming DFU launch. Financially, the transaction will be immediately accretive: our initial math suggests EPS accretion of $0.25-$0.30 in 2016."

For an analyst ratings summary and ratings history on Integra LifeSciences click here. For more ratings news on Integra LifeSciences click here.

Shares of Integra LifeSciences closed at $68.98 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments, Mergers and Acquisitions

Related Entities

Jefferies & Co, Definitive Agreement